Latest Second Genome Inc. Stories
SGM-1019 is an oral small molecule inhibitor of a target identified by company's Microbiome Discovery Platform SOUTH SAN FRANCISCO, Jan.
Mayo Clinic to Provide Clinical Expertise across Multiple Disease Indications SOUTH SAN FRANCISCO, Calif., Oct.
Former Pfizer Executive to Lead R&D at Second Genome SOUTH SAN FRANCISCO, Calif., Sept.
- An imitative word; an onomatopoetic word.